A closer look at pathogenesis of cerebral mucormycosis in diabetic condition: A mini review.
Mucorales
cerebral mucormycosis
diabetes
pathogenesis
Journal
Journal of basic microbiology
ISSN: 1521-4028
Titre abrégé: J Basic Microbiol
Pays: Germany
ID NLM: 8503885
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
22
11
2020
revised:
28
12
2020
accepted:
02
01
2021
pubmed:
16
1
2021
medline:
4
11
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
Patients with diabetes are considered a high-risk group involved with cerebral mucormycosis (CM). Due to the potential of Mucorales to invade sinuses and its rapid progression into orbit and retro-orbital areas and even brain, in most cases, CM is fatal in patients with diabetes. In the last few decades, mucormycosis and background conditions responsible for the development of its infections have received a great deal of attention. Dysfunction of innate and adaptive immune system, the increased amount of available nutrition, expression of host factors, and free iron level in plasma in diabetic ketoacidosis are among the topics that have been mostly taken into account so far. Therefore, it is important to clarify the molecular mechanisms that let the Mucorales to involve the patients with diabetes, which even at early stages of diagnosis and treatment, there is minimum chance to control the disease.
Identifiants
pubmed: 33448040
doi: 10.1002/jobm.202000692
doi:
Substances chimiques
Iron
E1UOL152H7
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
212-218Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091-100.
Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int. 2003;53:744-50.
Chikley A, Ben-Ami R, Kontoyiannis DP. Mucormycosis of the central nervous system. J Fungi (Basel). 2019;5:59.
Ibrahim AS. Host-iron assimilation: pathogenesis and novel therapies of mucormycosis. Mycoses. 2014;57:13-7.
Ibrahim AS. Host cell invasion in mucormycosis: role of iron. Curr Opin Microbiol. 2011;14:406-11.
Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-17.
Chow V, Khan S, Balogun A, Mitchell D, Mühlschlegel FA. Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient-the need for prompt treatment. Med Mycol Case Rep. 2015;8:5-9.
Chegini Z, Didehdar M, Khoshbayan A, Rajaeih S, Salehi M, Shariati A. Epidemiology, clinical features, diagnosis and treatment of cerebral mucormycosis in diabetic patients: a systematic review of case reports and case series. Mycoses. 2020;63:1264-82.
Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57:395-402.
Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab. 2012;38:193-204.
Serris A, Danion F, Lanternier F. Disease entities in mucormycosis. J Fungi (Basel). 2019;5:23.
Toumi A, Larbi Ammari F, Loussaief C, Hadhri R, Ben Brahim H, Harrathi K, et al. Rhino-orbito-cerebral mucormycosis: five cases. Med Mal Infect. 2012;42:591-8.
Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep. 2012;14:423-34.
Prabhu R, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10:31-47.
Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg. 2002;127:22-31.
Bannykh SI, Hunt B, Moser F. Intra-arterial spread of Mucormycetes mediates early ischemic necrosis of brain and suggests new venues for prophylactic therapy. Neuropathology. 2018;38:539-41.
Higo T, Kobayashi T, Yamazaki S, Ando S, Gonoi W, Ishida M, et al. Cerebral embolism through hematogenous dissemination of pulmonary mucormycosis complicating relapsed leukemia. Int J Clin Exp Pathol. 2015;8:13639.
Economides MP, Ballester LY, Kumar VA, Jiang Y, Tarrand J, Prieto V, et al. Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): uncommon, with improved survival but still deadly often. J Infect. 2017;75:572-80.
Malik AN, Bi WL, McCray B, Abedalthagafi M, Vaitkevicius H, Dunn IF. Isolated cerebral mucormycosis of the basal ganglia. Clin Neurol Neurosurg. 2014;124:102-5.
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-69.
Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73:778-83.
Bouchara J, Oumeziane NA, Lissitzky J, Larcher G, Tronchin G, Chabasse D. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol. 1996;70:76-83.
Suganya R, Malathi N, Karthikeyan V, Janagaraj VD. Mucormycosis: a brief review. J Pure Appl Microbiol. 2019;13:161-5.
Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120:1914-24.
Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest. 2014;124:237-50.
Mallis A, Mastronikolis S, Naxakis S, Papadas A. Rhinocerebral mucormycosis: an update. Eur Rev Med Pharmacol Sci. 2010;14:987-92.
Alqarihi A, Gebremariam T, Gu Y, Swidergall M, Alkhazraji S, Soliman SSM, et al. GRP78 and integrins play different roles in host cell invasion during mucormycosis. mBio. 2020;11:11. https://doi.org/10.1128/mBio.01087-20
Park HR, Voigt K. Interaction of Zygomycetes with innate immune cells reconsidered with respect to ecology, morphology, evolution and infection biology: a mini-review. Mycoses. 2014;57:31-9.
Granja LFZ, Pinto L, Almeida CA, Alviano DS, da Silva MH, Ejzemberg R, et al. Spores of Mucor ramosissimus, Mucor plumbeus and Mucor circinelloides and their ability to activate human complement system in vitro. Med Mycol. 2010;48:278-84.
Alba-Loureiro TC, Munhoz CD, Martins JO, Cerchiaro GA, Scavone C, Curi R, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res. 2007;40:1037-44.
Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23:3-13.
Foss NT, Foss-Freitas M, Ferreira M, Cardili RN, Barbosa C, Foss MC. Impaired cytokine production by peripheral blood mononuclear cells in type 1 diabetic patients. Diabetes Metab. 2007;33:439-43.
Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. Curr Opin Infect Dis. 2013;26:508-15.
Potenza L, Vallerini D, Barozzi P, Riva G, Forghieri F, Zanetti E, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood. 2011;118:5416-9.
Schmidt S, Tramsen L, Perkhofer S, Lass-Flörl C, Röger F, Schubert R, et al. Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. J Infect Dis. 2012;206:135-9.
Chinn R, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun. 1982;38:1123-9.
Waldorf A, Ruderman N, Diamond R. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984;74:150-60.
Waldorf AR, Diamond RD. Cerebral mucormycosis in diabetic mice after intrasinus challenge. Infect Immun. 1984;44:194-5.
Levitz SM, Selsted ME, Ganz T, Lehrer RI, Diamond RD. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986;154:483-9.
Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715-22.
Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol. 2006;55:251-8.
Lax C, Pérez-Arques C, Navarro-Mendoza MI, Cánovas-Márquez JT, Tahiri G, Pérez-Ruiz JA, et al. Genes, pathways, and mechanisms involved in the virulence of Mucorales. Genes. 2020;11:317.
Ibrahim A, Spellberg B, Edwards J Jr. Iron acquisition: a novel prospective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21:620-5.
Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010;77:587-604.
Sugar AM. Agents of mucormycosis and related species. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases. 3rd edNew York, NY: Churchill Livingstone, Inc.; 1995. p. 2311-21.
Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53:3122-5.
Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58:1070-3.
Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE, et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest. 2016;126:2280-94.
Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis transferrin and iron availability. Diabetes. 1982;31:1109-14.
de Locht M, Boelaert JR, Schneider Y-J. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843-50.